At SOHO 2026, experts highlighted new findings and advances across diseases including lymphoma, myelodysplastic syndrome, and leukemia.
David Sallman, MD
Advertisement
Articles by David Sallman, MD
At SOHO 2026, David Sallman, MD, explained why ofirnoflast produced responses across MDS subtypes, including in a patient with TP53-mutant disease.
Advertisement
Latest Updated Articles
Ofirnoflast Shows Activity Across High-Risk Mutated MDS SubtypesSeptember 11th 2026
Advertisement
Advertisement
Trending on CancerNetwork
1
Reading a Changed Eye Examination and Impact on Therapy
2
FDA Expands Approval for Nogapendekin Alfa in BCG-Unresponsive NMIBC
3
VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors
4
The Promise of CERVINO, MajesTEC-3, and EXCALIBER-RRMM in Multiple Myeloma
5